Breaking News Instant updates and real-time market news.

RHHBY

Roche

$0.00

(0.00%)

, GSK

GlaxoSmithKline

$40.81

-0.5799 (-1.40%)

11:40
07/05/19
07/05
11:40
07/05/19
11:40

Trump says working on 'favored-nations clause' to lower drug prices

President Trump told reporters at the White House that his administration is working on a "favored-nations clause," or a system that would allow the U.S. to buy drugs based on the lowest prices paid by other countries. Publicly traded companies in the pharmaceutical space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).

RHHBY

Roche

$0.00

(0.00%)

GSK

GlaxoSmithKline

$40.81

-0.5799 (-1.40%)

AZN

AstraZeneca

$41.26

-0.73 (-1.74%)

JNJ

Johnson & Johnson

$140.78

-1.12 (-0.79%)

BMY

Bristol-Myers

$46.47

-0.03 (-0.06%)

NVS

Novartis

$90.75

-1.73 (-1.87%)

MRK

Merck

$86.32

-0.33 (-0.38%)

LLY

Eli Lilly

$113.67

-1.76 (-1.52%)

SNY

Sanofi

$43.56

-0.44 (-1.00%)

PFE

Pfizer

$44.03

-0.28 (-0.63%)

  • 06

    Jul

  • 11

    Jul

  • 16

    Jul

  • 16

    Jul

  • 25

    Jul

  • 25

    Jul

  • 29

    Jul

  • 30

    Jul

  • 30

    Jul

  • 30

    Jul

  • 06

    Aug

  • 18

    Aug

  • 19

    Aug

  • 26

    Aug

  • 28

    Aug

  • 29

    Aug

  • 02

    Sep

  • 09

    Sep

  • 16

    Sep

  • 16

    Sep

  • 20

    Sep

  • 23

    Sep

  • 25

    Sep

  • 02

    Oct

  • 04

    Nov

RHHBY Roche
$0.00

(0.00%)

06/21/19
WBLR
06/21/19
NO CHANGE
WBLR
Outperform
William Blair an 'aggressive' buyer of Exelixis on weakness from clinical miss
William Blair analyst Andy Hsieh is an "aggressive" buyer of Exelixis (EXEL) shares on weakness after the company's partner Roche (RHHBY) informed the company that the Phase III IMspire170 trial, which assesses the safety and efficacy of the combination of Cotellic and Tecentriq, did not meet the primary endpoint of progression-free survival in treatment-naive melanoma. Hsieh says that while the news is disappointing, he reiterates that his bullish thesis resides in Exelixis's growth potential, driven by the Cabometyx franchise. As a result, the melanoma clinical setback does not impact the analyst's stock outlook. Further, he points out that he and the Street have not modeled revenue contribution from the IMspire170 study. Hsieh keeps an Outperform rating on Exelixis.
06/20/19
DBAB
06/20/19
UPGRADE
DBAB
Buy
Roche upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank analyst Richard Parkes upgraded Roche to Buy from Hold saying the company's portfolio and pipeline should offset upcoming U.S. biosimilar launches. The analyst sees upside to consensus estimates.
06/20/19
LIBR
06/20/19
DOWNGRADE
LIBR
Hold
Roche downgraded to Hold from Buy at Liberum
Liberum analyst Graham Doyle downgraded Roche to Hold from Buy with a price target of 275 francs. The analyst says the shares are "no longer in bargain territory" and that there are a lack of catalysts to move them higher.
06/28/19
PIPR
06/28/19
DOWNGRADE
Target $250
PIPR
Neutral
Biogen downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst Christopher Raymond downgraded Biogen (BIIB) to Neutral from Overweight and lowered his price target for the shares to $250 from $280. The stock closed yesterday up $1.70 to $239.77. Piper's new neurologist survey data from Spherix Global Insights "spells bad news for both Tecfidera and Tysabri in the near and longer term," Raymond tells investors in a research note. For the first time in a long time, Tecfidera market share is projected to contract over the next six months, primarily at the hands of Novartis' (NVS) new entrant Mayzent, explains the analyst. Further, Raymond notes that while prior surveys have indicated a plateauing of Roche's (RHHBY) Ocrevus with Biogen's Tysabri "hanging in there," the most recent indications are for an accelerating Ocrevus with Tysabri the "clear loser." The analyst lowered his estimates for both Tecfidera and Tysabri and downgraded Biogen.
GSK GlaxoSmithKline
$40.81

-0.5799 (-1.40%)

05/13/19
JEFF
05/13/19
NO CHANGE
Target $95
JEFF
Buy
Gilead shares reflect 'undue bearish outlook,' says Jefferies
Gilead Sciences (GILD) is trading at a 10 times price-to-earnings multiple, which reflects an "undue bearish outlook," Jefferies analyst Michael Yee tells investors in a research note. He thinks the company's base HIV business growing to 2025 and then eroding is worth $60-$65 per share, and the rest of business -- HCV, filgotinib, Yescarta -- is worth $15-$20 per share. This implies the stock should be at $80-$85, says Yee. A bear case on the HIV business is $35-$40 per share, which assumes a full cliff post 2025 or GlaxoSmithKline (GSK) taking "massive" share with doublets and long-acting, adds the analyst. Yee keeps a Buy rating on Gilead with a $95 price target.
02/22/19
UBSW
02/22/19
DOWNGRADE
UBSW
Neutral
GlaxoSmithKline downgraded to Neutral from Buy at UBS
UBS analyst Laura Sutcliffe downgraded GlaxoSmithKline to Neutral and lowered her price target for the shares to 1,650p from 1,700p. Concerns around the company's HIV franchise are likely to keep a lid on the shares, Sutcliffe tells investors in a research note. Further, she believes consensus estimates for 2019 are "slightly too high."
06/17/19
MSCO
06/17/19
INITIATION
MSCO
Underweight
GlaxoSmithKline resumed with an Underweight at Morgan Stanley
Morgan Stanley analyst Mark Purcell resumed coverage of GlaxoSmithKline (GSK) with an Underweight rating and 1,520p price target, citing his view that the company's pipeline rebuilding is "very much a work-in-progress." While the Novartis (NVS) was successful in releasing trapped value with the spinout of Alcon (ALC), Purcell sees only "modest" upside from current levels for Glaxo via the value creation from the planned consumer healthcare spinout, he stated.
02/01/19
WELS
02/01/19
NO CHANGE
Target $46
WELS
Market Perform
Perrigo's ProAir opportunity 'may be vaporizing,' says Wells Fargo
Wells Fargo analyst David Maris noted that GlaxoSmithKline (GSK) launched an authorized generic of Ventolin on January 15 and he has now learned that Teva (TEVA) may have "surprisingly launched" an authorized generic of ProAir in response to the generic Ventolin pressure prior to Perrigo's (PRGO) approval. Pricing pressure from generic Ventolin, in addition to the launch of an authorized generic well ahead of Perrigo's own generic ProAir launch, seem to have significantly diminished Perrigo's generic ProAir opportunity, Maris tells investors. He keeps a Market Perform rating and $46 price target on Perrigo shares.
AZN AstraZeneca
$41.26

-0.73 (-1.74%)

05/29/19
HCWC
05/29/19
NO CHANGE
HCWC
Buy
AstraZeneca decision does not impact MEDI0457, says H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju says AstraZeneca's (AZN) decision to discontinue activities related to two new DNA-based cancer vaccine candidates from Inovio (INO) does not affect MEDI0457. AstraZeneca continues to pursue the development of MEDI0457, which is being evaluated in combination with durvalumab in multiple Phase 2 studies in HPV-related cancers, Selvaraju tells investors in a research note. Inovio is eligible to receive up to $700M potential milestone payments, including $250M related to MEDI0457, says the analyst. He reiterates a Buy rating on Inovio with a $13 price target.
05/29/19
CANT
05/29/19
NO CHANGE
Target $12
CANT
Overweight
Inovio milestones from Astra still worth up to $250M, says Cantor Fitzgerald
Inovio (INO) announced that it received notification from MedImmune, a subsidiary of AstraZeneca (AZN), that it plans to discontinue research collaboration programs except for the MEDI0457/ durvalumab combo studies that are in multiple Phase 2 trials in patients with HPV associated cancers, Cantor Fitzgerald analyst Charles Duncan tells investors in a research note. Despite "strained optics," the collaboration change makes sense, says the analyst. He estimates Inovio's MEDI0457 milestones are worth up to $250M and keeps an Overweight rating on the shares with a $12 price target.
05/30/19
GUGG
05/30/19
NO CHANGE
GUGG
Buy
Array BioPharma could be seen as target after 'de-risking' data, says Guggenheim
Guggenheim analyst Michael Schmidt said Array Biopharma (ARRY) may be perceived by investors as a theoretical acquisition target following the disclosure of Phase 3 interim results of Braftovi/Mektovi in BRAF+ colorectal cancer, which he views as positive and a "de-risking event." 67% of announced acquisitions in oncology with a comparable market cap to Array had what he would consider major pipeline de-risking events in the 6 months prior to their deal announcements, Schmidt tells investors. Merck (MRK) and Pfizer (PFE) "seem to have most bandwidth for a deal," said Schmidt, who added that those two along with Bristol-Myers (BMY), AstraZeneca (AZN) and Roche (RHHBY) scored highest as possible large cap theoretical acquirers of Array in his analysis. Schmidt raised his price target on Array Biopharma shares to $38 from $37, though his analysis suggests a potential $40-$50 acquisition price if the company were to be bought.
05/30/19
SBSH
05/30/19
NO CHANGE
Target $7
SBSH
Buy
Inovio risk/reward attractive into data readouts, says Citi
Citi analyst Joel Beatty lowered his price target for Inovio Pharmaceuticals (INO) to $7 from $10 after AstraZeneca (AZN) decided to discontinue activities with respect to its rights to co-develop up to two new DNA-based cancer vaccine product candidates. The analyst, however, says this is a good time to buy shares of Inovio. The company has three phase 1/2 immuno-oncology combo trials expected to readout in the second half of 2019, and the stock's risk/reward is attractive into the news, Beatty tells investors in a research note.
JNJ Johnson & Johnson
$140.78

-1.12 (-0.79%)

05/30/19
COWN
05/30/19
NO CHANGE
Target $155
COWN
Outperform
Johnson & Johnson weakness may be overdone, says Cowen
Cowen analyst Joshua Jennings noted the State of Oklahoma is claiming Janssen Pharmaceuticals helped fuel the US opioid crisis which then caused volatility in Johnson & Johnson (JNJ) shares. While JNJ maintains its involvement was limited, the analyst says it is challenging to estimate the potential liability. His analysis however suggests, the stock's pullback is overdone. Jennings maintained his Outperform rating and $155 price target on Johnson & Johnson shares.
05/28/19
GSCO
05/28/19
INITIATION
Target $163
GSCO
Buy
Johnson & Johnson initiated with a Buy at Goldman Sachs
Goldman Sachs analyst Terence Flynn started Johnson & Johnson with a Buy rating and $163 price target. J&J's diversified portfolio is a potential strength as it results in the company having the lowest exposure to Medicare/Medicaid within the group, Flynn tells investors in a research note. As a result, he thinks the stock will be less impacted by potential drug pricing headlines/policy proposals ahead of the 2020 presidential election.
05/22/19
WELS
05/22/19
NO CHANGE
WELS
Wells Fargo says start of opioid trial won't be positive for Teva shares
Wells Fargo analyst David Maris noted that the nation's first major opioid case, brought against Teva (TEVA) and Johnson & Johnson (JNJ) in Oklahoma, will begin on May 28 and that the entire trial will be webcast. He thinks that the trial start and the opening webcast statements "will not be positive for Teva shares," adding that he suspects the outcome of this suit will be extrapolated to the Multi-District Litigation coming this fall. Maris keeps a Market Perform rating on Teva shares.
05/30/19
WELS
05/30/19
NO CHANGE
WELS
Outperform
Johnson & Johnson concerns over opioid case seem 'overblown,' says Wells Fargo
As the first state opioid trial begins in Oklahoma, Wells Fargo analyst Larry Biegelsen continues to believe that litigation will be manageable for Johnson & Johnson given its size and resources. The analyst notes that it appears the company's pain products - Duragesic patch and Nucynta/ER - accounted for less than 1% of the Oklahoma Medicaid opioid prescriptions from 1996-2017, while the company's slides also show data that fentanyl and tapentadol have lower abuse rates and diversion rates versus oxycodone and hydrocodone. Overall, Biegelsen believes concerns over the Oklahoma opioid case "may be overblown." The analyst has an Outperform rating on the shares.
BMY Bristol-Myers
$46.47

-0.03 (-0.06%)

05/28/19
GSCO
05/28/19
DOWNGRADE
Target $60
GSCO
Sell
Goldman sees negative sales growth for Gilead, downgrades shares to Sell
Goldman Sachs analyst Terence Flynn downgraded Gilead Sciences (GILD) to Sell from Neutral and lowered his price target for the shares to $60 from $70. The analyst expects Gilead's sales growth to decelerate saying the Truvada/Atripla loss of exclusivities in Sept ember 2020 represents a $3B headwind. Further, Biktarvy can only protect about half of the company's $16B HIV franchise from generic competition, Flynn tells investors in a research note. As a result, the analyst models annual revenue growth for Gilead through 2022 as negative 5%, which he notes is among the lowest in his coverage universe. Meanwhile, the stock trades at a slight premium to other stocks such as Bristol-Myers (BMY) and AbbVie (ABBV), says Flynn.
06/25/19
WBLR
06/25/19
NO CHANGE
WBLR
Outperform
Bristol-Myers sentiment suffered 'double hit' yesterday, says William Blair
William Blair analyst Matt Phipps said Bristol-Myers (BMY) suffered a "double hit to sentiment" yesterday with the news of both the CheckMate-459 trial failure in first-line hepatocellular carcinoma and delay of the closing of its Celgene (CELG) deal due to the required Otezla divestiture. He had previously modeled Opdivo sales in the front-line setting of over $1B and Otezla sales growing to $3B before loss of exclusivity in 2028 and decreased his out-year EPS estimates by over $1.00 due to yesterday's news. However, although near-term sentiment is dampened, he still sees a long-term opportunity, said Phipps, who keeps an Outperform rating on Bristol-Myers shares.
06/24/19
CANT
06/24/19
NO CHANGE
Target $100
CANT
Neutral
Celgene pushback surprising, but deal should still close, says Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young said she was surprised by the FTC pushback around Otezla and its overlap in psoriasis related to Celgene's (CELG) oral TYK2 program BMS-986165 in psoriasis given that the latter has not yet reported Phase 3 data. After speaking to Bristol-Myers (BMY), Young said management was also disappointed in this FTC decision, which they said was not related to current asset Orencia marketed for rheumatoid arthritis, juvenile idiopathic arthritis, and psoriatic arthritis. Though timelines are delayed, she still sees "a high likelihood" that the deal closes, but potentially 4-6 months behind schedule. Young, who sees many players in Inflammation & Immunology that could leverage oral Otezla with their existing salesforce, added that Bristol may not lose much in value from this divestiture if the process is competitive. She keeps a Neutral rating and $100 price target on Celgene shares.
NVS Novartis
$90.75

-1.73 (-1.87%)

06/14/19
PIPR
06/14/19
NO CHANGE
Target $120
PIPR
Neutral
Price tag of Bluebird's Zynteglo 'hard to justify,' says Piper Jaffray
The $1.8M price tag of Bluebird Bio's Zynteglo is "hard to justify" given the $2.1M comp of Novartis' (NVS) Zolgensma, which treats children with a certain outcome of death, as opposed to a population where the majority of patients are adequately maintained on transfusions, Piper Jaffray analyst Tyler Van Buren tells investors in a research note. In Zynteglo clinical trials, only 60 beta-thal patients have been enrolled and 16 sickle cell patients have ever been infused, the analyst points out. Yet, says Van Buren, the Street is modeling that Bluebird transplants thousands of patients with Zynteglo. He continues to believe uptake of the gene therapy will be challenging and keeps a Neutral rating on Bluebird Bio with a $120 price target.
06/03/19
06/03/19
DOWNGRADE

Perform
Aduro Biotech downgraded to Perform on lack of catalysts at Oppenheimer
As previously reported, Oppenheimer analyst Mark Breidenbach downgraded Aduro Biotech (ADRO) to Perform from Outperform given the company's lack of near-term catalysts. The analyst notes that Aduro's partner Novartis (NVS) presented initial clinical results from an ongoing Phase 1b trial of ADU-S100 in combination with spartalizumab in advanced tumors at ASCO. Given the pretreatment history of these patients, he cannot state with confidence that the responses observed were dependent on ADUS100, and the trial data suggests dosing has not yet been fully optimized. As Novartis continues to evaluate the STING agonist, Breidenbach anticipates an extended development timeline.
06/18/19
06/18/19
DOWNGRADE

Hold
Regeneron downgraded to Hold at Argus on mounting threats to Eylea
As previously reported, Argus analyst Jasper Hellweg downgraded Regeneron (REGN) to Hold from Buy, saying that while the company has a "strong pipeline" with new recent indications for multiple products, its primary revenue driver Eylea is facing several competitive threats. The analyst notes that Novartis (NVS) could launch a biologic designed to treat Eylea's key indication of wet age-related macular degeneration by the end of Q2 and also notes that the drug's patents are set to expire in 2022 in China and Japan, 2023 in the U.S., and 2024 in Europe. Hellweg adds that he will return his Regeneron rating to Buy if the company demonstrates that it can offset the impact of reduced Eylea sales, which accounted for over 75% of total revenue in Q1.
MRK Merck
$86.32

-0.33 (-0.38%)

07/03/19
MZHO
07/03/19
INITIATION
Target $97
MZHO
Buy
Mizuho starts Merck with Buy rating, $97 price target
Mizuho analyst Mara Goldstein last night initiated coverage of Merck with a Buy rating and $97 price target. The company is larger than Keytruda, but the "drug is too big to ignore," Goldstein tells investors in a research note. She believes Merck can overcome the loss of exclusivity on its Januvia franchise given Keytruda's "dominance" in immuno-oncology. The latter will drive operating margin expansion over the next five years, contends Goldstein.
07/02/19
MZHO
07/02/19
INITIATION
Target $97
MZHO
Buy
Merck initiated with a Buy at Mizuho
Mizuho started Merck with a Buy rating and $97 price target.
06/21/19
BOFA
06/21/19
NO CHANGE
Target $96
BOFA
Buy
Merck price target raised to $96 from $91 at BofA/Merrill
BofA/Merrill Lynch analyst Jason Gerberry raised his price target on Merck shares to $96 from $91 following the company's investor day meeting, stating that management conveyed a slightly more bullish outlook on margins and key revenue growth drivers at the event. He now thinks Merck will achieve about 40% operating margins by 2023, up from his prior 37.5% view, and also raised his out-year Gardasil estimates and factored in V114 risk-adjusted peak sales at $0.8B following the meeting. Gerberry keeps a Buy rating on Merck shares.
07/03/19
07/03/19
NO CHANGE

Fly Intel: Top five analyst actions
Catch up on today's top five analyst actions with this list compiled by The Fly: 1. Gol Linhas (GOL) upgraded to Buy from Neutral at Goldman Sachs with analyst Bruno Amorim saying the suspension of Avianca Brasil's operations on May 24 should provide a "significant boost" to unit revenues in the Brazilian domestic market in upcoming quarters. 2. Cinemark (CNK) upgraded to Buy from Hold at Loop Capital with analyst Alan Gould saying the "tough" comp facing the company in Q2 is now priced into the shares. 3. Latam Airlines (LTM) downgraded to Sell from Neutral at Goldman Sachs with analyst Bruno Amorim saying "fierce" competition in the Spanish speaking countries and "still weak" pricing in the international markets will likely offset the positive effect from Avianca Brasil's bankruptcy. 4. Inogen (INGN) downgraded to Underweight from Neutral at JPMorgan with analyst Robert Marcus, who continues to view Inogen as a "potentially attractive story" longer-term, saying he believes the company's near-term outlook is weighed down by uncertainty and market headwinds. 5. Merck (MRK) initiated with a Buy rating and a $97 price target at Mizuho. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
LLY Eli Lilly
$113.67

-1.76 (-1.52%)

05/28/19
GSCO
05/28/19
INITIATION
Target $135
GSCO
Buy
Eli Lilly initiated with a Buy at Goldman Sachs
Goldman Sachs analyst Terence Flynn started Eli Lilly with a Buy rating and $135 price target. The company has new product cycles in four large and growing therapeutic categories - diabetes, cancer, pain and immunology, Flynn tells investors in a research note. He believes investors are underappreciating Eli Lilly's longer-term growth potential in diabetes.
06/11/19
JPMS
06/11/19
NO CHANGE
JPMS
Overweight
Eli Lilly Rewind data missed 'fairly high' expectations, says JPMorgan
JPMorgan analyst Chris Schott is not surprised by the weakness yesterday in shares of Eli Lilly as he believes the Rewind data came in below "fairly high" expectations. However, the analyst ultimately sees the data confirming a cardiovascular benefit for Trulicity and supporting "continued strong Trulicity/GLP-1 uptake." Further, Schott sees the tirzepatide data at the American Diabetes Association conference as continuing to highlight a potentially best in class efficacy profile for the product. Lilly remains the analyst's top pick in his pharma coverage.
06/11/19
LEHM
06/11/19
UPGRADE
LEHM
Equal Weight
Novo Nordisk upgraded to Equal Weight from Underweight at Barclays
Barclays analyst Emmanuel Papadakis upgraded Novo Nordisk (NVO) to Equal Weight from Underweight and raised his price target for the shares to 325 kronor from 275 kronor. The analyst views competitor updates at the American Diabetes Association conference, specifically from Eli Lilly (LLY), as "underwhelming."
05/30/19
WELS
05/30/19
NO CHANGE
WELS
U.S. generic data continues to show challenging environment, says Wells Fargo
Wells Fargo analyst David Maris says that according to April IQVIA data, Teva (TEVA) U.S. generic sales were down 19% in April year over year, while brands sales were down 15%. Additionally, according to IQVIA data, Teva recently ceded its second place U.S. prescription market share place to competitor Eli Lilly (LLY) for its migraine drug, Ajovy, he points out. For Mylan (MYL), Maris says the monthly trends also paint a negative picture, with IQVIA U.S. generic sales in April down 36%. Nonetheless, the analyst believes Teva and Mylan shares seem to be reflecting an "aggressively negative outlook" given the current earnings multiples, and setting aside the worst-case outcomes in the opioid and price fixing cases, these may be at or nearing attractive valuations. However, for now, he remains on the sidelines, and within generics, continues to recommend Outperform-rated Amphastar (AMPH).
SNY Sanofi
$43.56

-0.44 (-1.00%)

06/18/19
06/18/19
DOWNGRADE

Sanofi downgraded to Hold from Buy at Intrinsic Health
06/18/19
ROTH
06/18/19
INITIATION
Target $25
ROTH
Buy
Translate Bio initiated with a Buy at Roth Capital
Roth Capital analyst Tony Butler started coverage of Translate Bio (TBIO) with a Buy rating and a $25 price target. The analyst believes that with its engineered mRNA and LPN delivery vehicles, Translate Bio's MRT platform has the advantages of enhanced stability, lower immunogenicity, tissue-specific delivery, and potentially scalable manufacturing. Butler also sees Sanofi (SNY) partnership providing resources and broadening the pipeline.
06/20/19
NOMU
06/20/19
NO CHANGE
Target $37
NOMU
Buy
Voyager Therapeutics price target raised to $37 from $26 at Nomura Instinet
Nomura Instinet analyst Christopher Marai raised his price target for Voyager Therapeutics (VYGR) to $37 from $26 after the company announced a restructured deal with Sanofi (SNY). Voyager now has worldwide rights to VY-HTT01 for Huntington's disease, and the ex-U.S. rights to VYFXN01 for Friedreich's ataxia have now been transferred to Neurocrine (NBIX), Marai tells investors in a research note. He believes obtaining the full rights to HTT01 is a positive for Voyager, especially after Roche (RHHBY) "posted positive derisking data." Marai reiterates a Buy rating on Voyager Therapeutics.
06/21/19
STFL
06/21/19
DOWNGRADE
Target $74
STFL
Hold
AnaptysBio downgraded to Hold from Buy at Stifel
Stifel analyst Derek Archila downgraded AnaptysBio (ANAB) to Hold from Buy as he is less confident etokimab will be meaningfully differentiated from Sanofi (SNY) and Regeneron's (REGN) Dupixent after the latter companies reported results from their Phase 2 study for REGN3500, an antiIL-33 antibody, in asthma. REGN3500 did numerically worse than Dupixent as a monotherapy and the combination of REGN3500/Dupixent did not confer a benefit over Dupixent alone, noted Archila. He lowered his view on the odds of success for etokimab to 50% from 55% and also cut his market share assumptions following the competitors' data. Archila cut his price target on AnaptysBio shares to $74 from $124.
PFE Pfizer
$44.03

-0.28 (-0.63%)

06/28/19
WBLR
06/28/19
NO CHANGE
WBLR
Outperform
Sarepta has clear lead in DMD after Pfizer disappoints, says William Blair
William Blair analyst Tim Lugo calls Sarepta Therapeutics (SRPT) the "clear leader" in Duchenne muscular dystrophy without a close number two after this morning's results from Pfizer (PFE) disappointed. Shares of Sarepta are up 15%, or $20.04, to $149.80 in midday trading.
06/28/19
PIPR
06/28/19
NO CHANGE
Target $208
PIPR
Overweight
'Almost impossible' for Pfizer to compete with Sarepta, says Piper Jaffray
Sarepta Therapeutics (SRPT) went from the front-runner to "basically a standalone" in the Duchenne muscular dystrophy gene therapy race after this morning's data from Pfizer (PFE) showed "serious safety signals" that led to hospitalization in two of six patients dosed, Piper Jaffray analyst Danielle Brill tells investors in a research note. And while Pfizer believes complement activation was driven by a high presence of neutralizing antibodies, the serious adverse event was also observed with Solid Biosciences' (SLDB) gene therapy, which employs the same vector as Pfizer, adds the analyst. As a result, Brill thinks complement activation may be AAV9 related, especially since no such signal has been seen with Sarepta's AAVrh74 vector. In addition, Pfizer has no edge over Sarepta on efficacy either, says the analyst. She thinks it will be "almost impossible" for Pfizer to compete moving forward and reiterates an Overweight rating on Sarepta with a $208 price target. The stock in afternoon trading is up 16%, or $20.61, to $150.37.
06/28/19
NOMU
06/28/19
NO CHANGE
Target $22
NOMU
Buy
Solid Biosciences should benefit from positive Pfizer data, says Nomura Instinet
Pfizer (PFE) is scheduled to provide an update this morning on its mini-dystrophin gene therapy, PF-06939926, Nomura Instinet analyst Christopher Marai tells investors in a research note. The analyst sees positive read-through to Solid Biosciences' (SLDB) SGT-001 program from potential positive Pfizer data, as both programs use the AAV9 capsid. He believes that capsid type is likely the strongest factor that determines expression level at a given dose. As a result, Pfizer's dose-expression relationship should provide key insight into expectations for Solid Biosciences' higher dose, says Marai. He keeps a Buy rating on Solid shares with a $22 price target.
06/28/19
JPMS
06/28/19
NO CHANGE
JPMS
Overweight
Sarepta 'still in pole position' in DMD after Pfizer data, says JPMorgan
JPMorgan analyst Anupam Rama said that Sarepta (SRPT) is "still in the pole position" in Duchenne muscular dystrophy, or DMD, after Pfizer (PFE) presented preliminary data from its own ongoing Phase 1b study of DMD gene therapy PF-06939926. Rama has an Overweight rating on Sarepta shares.

TODAY'S FREE FLY STORIES

RACE

Ferrari

$168.55

2.05 (1.23%)

21:17
07/15/19
07/15
21:17
07/15/19
21:17
Recommendations
Ferrari analyst commentary at Goldman Sachs »

Ferrari price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RNLSY

Renault

$0.00

(0.00%)

21:12
07/15/19
07/15
21:12
07/15/19
21:12
Initiation
Renault initiated at Goldman Sachs »

Renault initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PUGOY

Peugeot

$0.00

(0.00%)

21:07
07/15/19
07/15
21:07
07/15/19
21:07
Initiation
Peugeot initiated at Goldman Sachs »

Peugeot initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTES

NetEase

$256.35

-3.62 (-1.39%)

21:02
07/15/19
07/15
21:02
07/15/19
21:02
Hot Stocks
NetEase acquires minority stake in Behaviour Interactive, terms not stated »

NetEase Games announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCAU

Fiat Chrysler

$14.18

0.045 (0.32%)

20:57
07/15/19
07/15
20:57
07/15/19
20:57
Initiation
Fiat Chrysler initiated at Goldman Sachs »

Fiat Chrysler initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

DDAIF

Daimler AG

$0.00

(0.00%)

20:53
07/15/19
07/15
20:53
07/15/19
20:53
Initiation
Daimler AG initiated at Goldman Sachs »

Daimler AG initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMWYY

BMW

$0.00

(0.00%)

20:48
07/15/19
07/15
20:48
07/15/19
20:48
Initiation
BMW initiated at Goldman Sachs »

BMW initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VALE

Vale

$13.99

0.175 (1.27%)

20:38
07/15/19
07/15
20:38
07/15/19
20:38
Periodicals
Vale to pay $106.5M to Brazil workers impacted by dam incident, Reuters says »

Vale disclosed that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

RNR

RenaissanceRe

$187.35

3.295 (1.79%)

20:36
07/15/19
07/15
20:36
07/15/19
20:36
Downgrade
RenaissanceRe rating change at Deutsche Bank »

RenaissanceRe downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

JPM

JPMorgan

$113.87

-1.45 (-1.26%)

, JNJ

Johnson & Johnson

$134.67

0.38 (0.28%)

20:25
07/15/19
07/15
20:25
07/15/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

JPM

JPMorgan

$113.87

-1.45 (-1.26%)

JNJ

Johnson & Johnson

$134.67

0.38 (0.28%)

WFC

Wells Fargo

$46.70

-0.65 (-1.37%)

GS

Goldman Sachs

$211.55

-2.4 (-1.12%)

PLD

Prologis

$79.94

-0.09 (-0.11%)

FRC

First Republic

$98.61

-2.02 (-2.01%)

DPZ

Domino's Pizza

$269.97

-12.26 (-4.34%)

SNV

Synovus

$34.35

-1.08 (-3.05%)

FHN

First Horizon

$14.80

-0.305 (-2.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Jul

  • 16

    Jul

  • 16

    Jul

  • 16

    Jul

  • 16

    Jul

  • 16

    Jul

  • 16

    Jul

  • 16

    Jul

  • 16

    Jul

  • 16

    Jul

  • 29

    Jul

  • 30

    Jul

  • 06

    Aug

  • 27

    Aug

  • 28

    Aug

  • 06

    Sep

  • 09

    Sep

  • 16

    Sep

  • 23

    Sep

  • 12

    Oct

  • 13

    Nov

SON

Sonoco

$64.49

-0.69 (-1.06%)

20:04
07/15/19
07/15
20:04
07/15/19
20:04
Downgrade
Sonoco rating change at BMO Capital »

Sonoco downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 06

    Aug

  • 17

    Oct

SON

Sonoco

$64.49

-0.69 (-1.06%)

19:59
07/15/19
07/15
19:59
07/15/19
19:59
Downgrade
Sonoco rating change at BMO Capital »

Sonoco downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 06

    Aug

  • 17

    Oct

PLD

Prologis

$79.94

-0.09 (-0.11%)

19:51
07/15/19
07/15
19:51
07/15/19
19:51
Hot Stocks
Prologis to buy Black Creek Group industrial RE investment platform for $3.99B »

Black Creek Group has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

PLD

Prologis

$79.94

-0.09 (-0.11%)

19:48
07/15/19
07/15
19:48
07/15/19
19:48
Earnings
Prologis reports Q2 FFO 77c, consensus 76c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

CVX

Chevron

$125.71

-0.27 (-0.21%)

19:46
07/15/19
07/15
19:46
07/15/19
19:46
Hot Stocks
Chevron ordered to stop oil spill in California by State Regulator »

California Natural…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

GPL

Great Panther Silver

$0.72

-0.0409 (-5.38%)

19:33
07/15/19
07/15
19:33
07/15/19
19:33
Hot Stocks
Great Panther Silver names Jeffrey Mason as new board chair »

Great Panther Silver…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PYPL

PayPal

$120.88

0.77 (0.64%)

19:04
07/15/19
07/15
19:04
07/15/19
19:04
Hot Stocks
PayPal launches international money transfer service Xoom »

PayPal launched Xoom-its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

JBHT

J.B. Hunt

$92.50

-0.45 (-0.48%)

, EYEN

Eyenovia

$2.89

0.04 (1.40%)

18:58
07/15/19
07/15
18:58
07/15/19
18:58
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: JB…

JBHT

J.B. Hunt

$92.50

-0.45 (-0.48%)

EYEN

Eyenovia

$2.89

0.04 (1.40%)

VKTX

Viking Therapeutics

$8.25

0.02 (0.24%)

ARW

Arrow Electronics

$68.82

-0.15 (-0.22%)

ATEX

Anterix

$47.61

0.61 (1.30%)

RGEN

Repligen

$85.87

0.86 (1.01%)

MPW

Medical Properties Trust

$18.28

-0.23 (-1.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Jul

  • 24

    Jul

  • 25

    Jul

  • 06

    Aug

  • 08

    Aug

  • 09

    Aug

  • 26

    Aug

  • 09

    Sep

  • 18

    Sep

  • 19

    Sep

  • 13

    Nov

  • 16

    Jul

  • 17

    Jul

  • 17

    Jul

WTFC

Wintrust Financial

$69.99

-2.05 (-2.85%)

18:56
07/15/19
07/15
18:56
07/15/19
18:56
Earnings
Wintrust Financial reports Q2 EPS $1.38, consensus $1.66 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 06

    Aug

DDAIF

Daimler AG

$0.00

(0.00%)

18:46
07/15/19
07/15
18:46
07/15/19
18:46
Initiation
Daimler AG initiated at Goldman Sachs »

Daimler AG initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PUGOY

Peugeot

$0.00

(0.00%)

18:46
07/15/19
07/15
18:46
07/15/19
18:46
Initiation
Peugeot initiated at Goldman Sachs »

Peugeot initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCAU

Fiat Chrysler

$14.18

0.045 (0.32%)

18:45
07/15/19
07/15
18:45
07/15/19
18:45
Initiation
Fiat Chrysler initiated at Goldman Sachs »

Fiat Chrysler initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

TGI

Triumph Group

$23.07

-0.22 (-0.94%)

18:42
07/15/19
07/15
18:42
07/15/19
18:42
Hot Stocks
Triumph Group selected by leading airline as MRO provider »

Triumph Group announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 31

    Jul

TRQ

Turquoise Hill

$1.07

-0.02 (-1.83%)

18:32
07/15/19
07/15
18:32
07/15/19
18:32
Hot Stocks
Turquoise Hill reports Q2 copper output 39.2KT, down 0.6% from last year »

Reports Q2 Gold output…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RIO

Rio Tinto

$61.50

0.77 (1.27%)

18:29
07/15/19
07/15
18:29
07/15/19
18:29
Hot Stocks
Rio Tinto cuts FY19 Pilbara ore shipments view to 320M-330M tons »

Prior view was 333M-343M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.